Home/Pipeline/Discovery Program (Unnamed)

Discovery Program (Unnamed)

Sarcopenia (age-related muscle wasting)

DiscoveryActive

Key Facts

Indication
Sarcopenia (age-related muscle wasting)
Phase
Discovery
Status
Active
Company

About Altagenics

Altagenics represents a strategic venture by GLD Partners LP to deploy transformational technologies that improve the economics and likelihood of success in drug discovery. By integrating the GigaAssay™ platform—which provides comprehensive, quantitative readouts of protein function and drug response—into a focused company structure, Altagenics aims to generate actionable datasets that rapidly translate into a differentiated pipeline. The company's scalable model is expected to yield thousands of novel, drug-like compounds targeting muscle health and degeneration, positioning it as a leader in muscle-targeted therapeutics with potential applications in sports medicine, rehabilitation, and metabolic health.

View full company profile

About Altagenics

Altagenics represents a strategic venture by GLD Partners LP to deploy transformational technologies that improve the economics and likelihood of success in drug discovery. By integrating the GigaAssay™ platform—which provides comprehensive, quantitative readouts of protein function and drug response—into a focused company structure, Altagenics aims to generate actionable datasets that rapidly translate into a differentiated pipeline. The company's scalable model is expected to yield thousands of novel, drug-like compounds targeting muscle health and degeneration, positioning it as a leader in muscle-targeted therapeutics with potential applications in sports medicine, rehabilitation, and metabolic health.

View full company profile